Allos Therapeutics, Inc. Release: Data On EFAPROXYN(TM) And RH1 To Be Presented At Upcoming Scientific Conferences

WESTMINSTER, Colo., Nov. 8 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that data evaluating the Company's product candidates EFAPROXYN (efaproxiral) and RH1 have been accepted for presentation at the following scientific conferences:

* AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Sarah Danson, M.D., Department of Medical Oncology, Christie Hospital, is scheduled to report updated clinical and PK/PD data from an on-going Phase 1 study of RH1 in patients with advanced solid tumors in a poster presentation titled "Phase 1 Pharmacokinetic (PD) trial of the bioreductive drug RH1" on Thursday, November 17. * San Antonio Breast Cancer Symposium: Charles Scott, Ph.D., CBS Squared, is scheduled to present a quality adjusted survival analysis of the Phase 3 REACH study of EFAPROXYN in patients with brain metastases in a poster presentation titled "Improved survival, quality of life and quality-adjusted survival in breast cancer patients treated with efaproxiral + whole brain radiation therapy for brain metastases" on Saturday, December 10.

Copies of the abstracts will be available on the AACR ( and SABCS ( web sites.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer. The Company's other product candidates are: PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor) currently under investigation as both a single agent and in combination therapy regimens in patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme DT-diaphorase currently under evaluation in patients with advanced solid tumors. For more information, please visit the Company's web site at:

Safe Harbor Statement

The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2004 and in the Company's periodic reports on Form 10-Q and Form 8-K. The Company does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Allos Therapeutics, Inc.

CONTACT: Jennifer Neiman, Manager, Corporate Communications of AllosTherapeutics, +1-720-540-5227,

Back to news